Amplia Communications, a privately owned Trinidadian company founded in 2017, provides pay TV services and other telecommunications services across the Caribbean. As of 2023, the company employed approximately 130 people and reported revenues of around $25 million. Its headquarters are located in Trinidad and Tobago.
On an unspecified date, Amplia Therapeutics initiated a pancreatic cancer trial, dosing the first patient in a study testing the FAK inhibitor narmafotinib (AMP945) in combination with chemotherapy. The trial opened at two Australian sites, with four US centers awaiting final approvals. On an unspecified Wednesday, Amplia Therapeutics shares declined approximately 20% following the release of clinical trial results, which the company considered positive, despite the market's negative reaction. The company's shares had more than tripled year-to-date prior to this decline. Separately, Amplia Electric Networks provided electrical networks to 240 families in Luyando Rupa Rupa and Mariano Damaso Beraun, Peru.
Similar Companies
Subscribe for full access to Amplia Communications's profile
Amplia Communications offers 4 products in the media and telecoms services industry. Amplia Communications's product portfolio comprises of media and TV services and telecoms services.
Subscribe for full access to Amplia Communications's products in full detail
Amplia Communications's revenues were less than $50M in 2023. Caretta Research has split Amplia Communications's revenue into 4 different product categories, the largest of which is enterprise broadband and voice. For full access to Amplia Communications's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Amplia Communications's revenue in full detail
Subscribe for full access to Amplia Communications's products in full detail 
